Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Diamyd appoints Peter Zerhouni as President The Board of Diamyd Medical has appointed Peter Zerhouni, Acting President of Diamyd Medical AB, as President of the Company. Peter Zerhouni has been...
-
Diamyd utser Peter Zerhouni till VD Diamyd Medicals styrelse har utsett Peter Zerhouni, tillförordnad VD i Diamyd Medical AB, till VD i bolaget. Peter Zerhouni har varit involverad i bolagets...
-
Quarterly Report III 10/11 Quarterly report, Stockholm, July 1, 2011 September 1, 2010 - May 31, 2011 Third quarter report for Diamyd Medical AB (publ.), fiscal year 2010/2011 (www.omxgroup.com...
-
Delårsrapport III 10/11 Delårsrapport Stockholm 1 juli 2011 1 september 2010 - 31 maj 2011 Delårsrapport 3 Diamyd Medical AB (publ.), räkenskapsåret 2010/2011 (www.omxgroup.com ticker: DIAM B;...
-
Diamyd increases shareholding in Protein Sciences Corporation Diamyd Medical AB announced today that the Company's convertible promissory note in the US vaccine company Protein Sciences...
-
Diamyd ökar aktieinnehavet i Protein Sciences Corporation Diamyd Medical meddelar idag att bolagets konvertibla skuldebrev i det amerikanska vaccinbolaget Protein Sciences Corporation, har...
-
Diamyd presents detailed results of European Phase III study Diamyd Medical AB reports detailed results from the Company's European Phase III study of the antigen-based diabetes therapy Diamyd®,...
-
Diamyd presenterar detaljerade resultat från europeisk fas III-studie Diamyd Medical AB meddelar de detaljerade resultaten från bolagets europeiska fas III-studie med den antigenbaserade...
-
TrialNet presents results from a study with Diamyd® Diamyd Medical AB reports that the results of a study with the Company's antigen-based diabetes therapy Diamyd®, conducted by the...
-
TrialNet presenterar resultat från studie med Diamyd® Diamyd Medical AB meddelar att resultaten av en studie med bolagets antigenbaserade diabetesterapi Diamyd® som genomförs av forskningskonsortiet...